Combination chemotherapy ( @entity1487 , methyl-CCNU, XXXX ) versus @entity1487 alone for advanced previously untreated @entity14 . A phase III study of the Piedmont Oncology Association.

@entity1 @entity137 @entity1138 @entity2098 @entity5498 @entity14 @entity1487
One-hundred thirty eligible @entity1 with advanced @entity14 who had received no prior chemotherapy were randomized to either @entity5498 -CCNU, 70 mg/m2 orally every 6 weeks on day 1, @entity1138 , 10 mg/m2 intravenously every 6 weeks on day 1, and @entity1487 ( @entity1487 ), 400 mg/m2 intravenously weekly--( @entity2098 )--or @entity1487 , 600 mg/m2 intravenously weekly ( @entity1487 ). One hundred twenty-six @entity1 are evaluable for response. Of 62 @entity1 treated with @entity2098 , one (2%) achieved complete remission, and three (5%) attained partial remission. Of 64 @entity1 treated with @entity1487 , two (3%) achieved complete remission, and eight (13%) attained partial remission. The median survival for @entity1 receiving @entity2098 was 9.5 months compared with 10.3 months for @entity1 receiving @entity1487 . The survival distributions for the two regimens were not significantly different, either unadjusted or adjusted for pretreatment characteristics. Performance status and lactic dehydrogenase (LDH) were both significantly associated with survival. @entity1 with liver metastases only and normal liver function tests had a median survival of 19.8 months and a 40% response rate. This randomized phase III trial did not show any therapeutic advantage for @entity2098 compared to @entity1487 therapy alone in advanced @entity14 . In addition, hematologic @entity137 was significantly greater with the combination ( @entity2098 ) regimen.
